Lpathomab

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameLpathomab
Drug Alias NameAnti-LPA MAbs - LpathLT-3000LT-3015
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionLysophosphatidic acid inhibitors
TargetsLysophosphatidic acid
Therapy Area/IndicationsNeuralgia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLpath Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Active IndicationsN/A
Inactive IndicationsNeuralgia

Other Information

ATC CodeN/A
Related LinksN/A